(Q62105371)
Statements
A Phase 1/2, Open Label, Dose Escalation Study of AQ4N for Safety, Tolerability, Pharmacokinetics and Activity in Patients With Lymphoid Neoplasms (English)
0 references
March 2005
0 references
55
0 references
18 year
0 references